
## **Novartis - Focus on Europe**



#### A therapeutic revolution for every decade



www.novartis.com



#### **Priority for R&D**

Novartis is reimagining medicine and is committed to delivering new treatments that transform patients' lives. Our approach to R&D pushes the boundaries of science to find solutions where there is unmet medical need in four main areas:



Cardiovascular, renal and metabolic



**Immunology** 

Oncology



clinical projects incl. 41 ongoing phase III programmes



€7.8 billion

R&D investments

## Novartis, a committed player in...\*

#### **Ethical standards**

Neuroscience

Novartis is committed to conducting thorough due diligence processes to identify. address, evaluate and communicate the risks of involvement with adverse human rights ethical and compliance issues.

#### **Equal opportunities**

WOMEN 51% 49% **Novartis** Novartis 48% management management

52%

MEN

#### **Environment**

Our ambition is to be a leader in environmental transition thanks to ambitious assembled targets for 2025 and 2030 involving our activities and those of our partners in the following areas:



**Carbon neutrality** 2025, use only renewable energy 2030 carbon neutrality across value chain



**Circular economy** 2025, waste reduced by 50% **2030**, plastic neutrality.



Water sustainability 2025, water consumption reduced by 50% 2030, water neutrality in own operations

\*For more info, see the Novartis in Society Integrated Report 2023

#### Worldwide access

#### 284 million >1 billion

patients reached with Novartis medicines.

antimalarial treatments delivered without profit, including 450 M in pediatrics.

#### >7.5 million

leprosy patients benefiting from free polytherapy to eradicate the disease the disease over the past 20 years

### €89.2 million

invested in R&D for malaria and neglected tropical diseases.

### lop5

in the Access to Medicines Index since 2014.

### **Novartis in Europe**\*



employees'



iobs created by Novartis\*\*



Novartis sites, from R&D to manufacturing, commercial to development

### 

€28.8 billion **GDP** contribution by Novartis

€39 billion total impact on GDP\*

30000 number of patients in clinical trials



41 Healthcare Initiative projects involve

\*European Union & Switzerland. \*\*Full Time Equivalent. \*\*\*Direct, indirect and induced.

#### **Sites in Europe** SWEDEN FINLAND Clinical trials locations Manufacturing sites REPUBLIC OF IRELAND ESTONIA Commercial LATVIA **Large Molecules Small Molecules** Cell & Gene NETHERLANDS LITHUANIA Puurs Schaftenau (2) Stein Târgu Mureş Kundl POLAND GERMANY SLOVAKIA Huningue Liubliana CZECHIA HUNGARY Menges Menges 20 AUSTRIA Saluggia Stein Schweizerhalle FRANCE 10.4 ROMANIA Baarle-Nassau Basel Stein Wehr 🔞 💶 Zaragoza BULGARIA PORTUGAL SPAIN ■ Torre SWITZERLAND SLOVENIA CROATIA MALTA

#### The EU in the current geopolitical context

Europe's resilience and economic security will depend on its ability to attract innovation.

We welcome the focus on security of supply and open strategic autonomy, and remain dedicated to reimagining medicines to provide patients with life-saving treatments all over the world.

Digital tools and Artificial Intelligence (AI) have become increasingly important when it comes to the development and delivery of medicines, and we are committed to be a frontrunner in this field.

We look forward to working with the new political leadership to make sure that Europe remains a leader in healthcare.



# What do we need to remain competitive?



# Ensuring (market) access and availability



Medicines have no value if they don't reach patients across the continent. The absorption of innovation by member states is therefore key.



Shortages are still happening and we need to tackle the root causes, together.



# Attractive IP and regulatory framework



Regulatory Data Protection is a key element for investment decisions. The General Pharmaceutical Legislation should not weaken this crucial incentive.



Prospective advanced therapies will need a future-proof system, and the use of digital tools, including AI, will be key.



### Level playing field on environmental legislation



We fully support the ambition of a greener Europe (and world). Europe needs to be a front-runner in environmental standards, but by upholding the industry's competitiveness.



New legislation should include adequate transition periods, and make sure that alternatives are available.



## Key EU initiatives that we are following/actively engaging:

- General Pharma Legislation
- Critical Medicines Alliance
- EU List of Critical Medicines
- European Green Deal, including Urban Waste Water Treatment Directive (UWWTD) and PFAS
- Biotech and Biomanufacturing initiative

## Other initiatives we are closely monitoring:

- · Patent package
- Al Act
- · Letta/ Draghi reports
- IPCFI "Med4Cure"
- CS3D/CSRD
- Antwerp Declaration

